Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Trimethoprim; Sulfadiazine
Norbrook Laboratories (Ireland) Limited
QJ01EW10
Trimethoprim; Sulfadiazine
24 percent weight/volume
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
sulfadiazine and trimethoprim
Authorised
1988-10-01
_ _ SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Norodine 24% Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substances Trimethoprim 40 mg Sulfadiazine 200 mg Excipients Chlorocresol 1 mg Sodium Formaldehyde Sulfoxylate 1 mg N-Methyl Pyrrolidone 0.5 ml For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. A clear, yellow aqueous solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses, cattle, pigs, cats and dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES The product is indicated in the treatment of systemic infections caused by or associated with organisms sensitive to the Trimethoprim : Sulphadiazine combination. The spectrum of activity includes both Gram positive and Gram negative organisms including Actinobacilli _Klebsiella _ spp. _Bordetella _ spp. _Pasteurella _ spp. Corynebacteria _Salmonella _ spp. _Eschericia coli_ Staphylococci _Haemophilus _ spp. Streptococci _ _ _ _ 4.3 CONTRAINDICATIONS The product should not be administered intraperitoneally. Do not administer to animals known to be hypersensitive to the active ingredients. Do not administer to animals with known sulphonamide sensitivity or severe liver or kidney parenchymal damage or blood dyscrasias. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Adequate drinking water should be available during the therapeutic effect of the product. Avoid the introduction of contamination during use. Should any apparent growth or discolouration occur the product should be discarded. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the produc Les hele dokumentet